Omnicell (NASDAQ:OMCL) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued to investors on Friday.
OMCL has been the topic of several other reports. Zacks Investment Research raised Omnicell from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 27th. Cantor Fitzgerald reissued a “buy” rating and set a $60.00 price objective on shares of Omnicell in a research note on Tuesday, December 5th. Oppenheimer reissued a “buy” rating and set a $55.00 price objective on shares of Omnicell in a research note on Thursday, October 19th. Finally, Craig Hallum reissued a “buy” rating and set a $62.00 price objective (up from $52.00) on shares of Omnicell in a research note on Monday, October 30th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $55.14.
Shares of Omnicell (OMCL) opened at $50.55 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.53 and a quick ratio of 1.08. The company has a market capitalization of $1,911.79, a PE ratio of -459.55, a P/E/G ratio of 4.00 and a beta of 0.71. Omnicell has a 52-week low of $32.70 and a 52-week high of $55.40.
Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, October 26th. The company reported $0.42 EPS for the quarter, hitting analysts’ consensus estimates of $0.42. Omnicell had a negative return on equity of 0.79% and a negative net margin of 0.51%. The company had revenue of $186.78 million for the quarter, compared to the consensus estimate of $192.45 million. During the same period in the previous year, the business earned $0.40 earnings per share. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. analysts anticipate that Omnicell will post 0.12 EPS for the current fiscal year.
In other news, CFO Peter J. Kuipers sold 1,926 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $51.69, for a total transaction of $99,554.94. Following the transaction, the chief financial officer now owns 40,544 shares of the company’s stock, valued at $2,095,719.36. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Dan S. Johnston sold 14,613 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $47.81, for a total value of $698,647.53. Following the transaction, the executive vice president now directly owns 43,621 shares in the company, valued at approximately $2,085,520.01. The disclosure for this sale can be found here. Insiders have sold 27,558 shares of company stock worth $1,330,230 over the last three months. 3.77% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Flinton Capital Management LLC grew its stake in shares of Omnicell by 74.6% during the second quarter. Flinton Capital Management LLC now owns 4,216 shares of the company’s stock valued at $182,000 after buying an additional 1,802 shares during the last quarter. Riverhead Capital Management LLC grew its stake in shares of Omnicell by 76.3% during the second quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock valued at $182,000 after buying an additional 1,830 shares during the last quarter. Marco Investment Management LLC bought a new position in shares of Omnicell during the third quarter valued at approximately $231,000. Pinebridge Investments L.P. grew its stake in shares of Omnicell by 1.6% during the second quarter. Pinebridge Investments L.P. now owns 4,896 shares of the company’s stock valued at $211,000 after buying an additional 76 shares during the last quarter. Finally, Amalgamated Bank bought a new position in shares of Omnicell during the second quarter valued at approximately $219,000. 99.61% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Omnicell (OMCL) Downgraded by BidaskClub to Strong Sell” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/19/omnicell-omcl-downgraded-by-bidaskclub-to-strong-sell.html.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.